Synthesis and biological evaluation of selective ErbB2 (Her2) inhibitors for the treatment of cancer

被引：0
|
作者：
Kauffman, Goss S. [1 ]
Lippa, Blaise [1 ]
Arcari, Joel [1 ]
Kwan, Tricia A. [1 ]
Bhattacharya, Samit K. [1 ]
Pustilnik, Leslie R. [1 ]
Su, Chunyan [1 ]
Moyer, James D. [1 ]
Ma, Ling [1 ]
Campbell, Mary [1 ]
Steyn, Stefan [1 ]
机构：
[1] Pfizer Global Res & Dev, Dept Canc Res, Groton, CT 06340 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2006年 / 231卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
245-MEDI
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Acral lentiginous melanoma with HER2/ErbB2 amplification
    Marie Donzel
    Olivier Harou
    François Skowron
    Stéphane Dalle
    Françoise Descotes
    Brigitte Balme
    Jonathan Lopez
    European Journal of Dermatology, 2021, 31 : 588 - 590
  • [22] Acral lentiginous melanoma with HER2/ErbB2 amplification
    Donzel, Marie
    Harou, Olivier
    Skowron, Francois
    Dalle, Stephane
    Descotes, Francoise
    Balme, Brigitte
    Lopez, Jonathan
    EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31 (04) : 588 - 590
  • [23] Prognostic value of ErbB2/HER2 in human meningiomas
    Arnli, Magnus B.
    Winther, Theo L.
    Lydersen, Stian
    Torp, Sverre H.
    PLOS ONE, 2018, 13 (10):
  • [24] Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
    Moutafi, Myrto
    Robbins, Charles J.
    Yaghoobi, Vesal
    Fernandez, Aileen, I
    Martinez-Morilla, Sandra
    Xirou, Vasiliki
    Bai, Yalai
    Song, Yan
    Gaule, Patricia
    Krueger, Joseph
    Bloom, Kenneth
    Hill, Salisha
    Liebler, Daniel C.
    Fulton, Regan
    Rimm, David L.
    LABORATORY INVESTIGATION, 2022, 102 (10) : 1101 - 1108
  • [25] Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer Close Enough?
    Burstein, Harold J.
    Schrag, Deborah
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (01): : 30 - 32
  • [26] Pan-cancer analysis of the influence of ERBB2 alteration on HER2 expression
    Lee, Taebum
    Shin, Sangwon
    Song, Heon
    Park, Seonwook
    Pereira, Sergio
    Yoo, Donggeun
    Ro, Juneyoung
    Moon, Jimin
    Cho, Soo Ick
    Ahn, Changho
    Ock, Chan-Young
    Ali, Siraj M.
    CANCER RESEARCH, 2023, 84 (06)
  • [27] HER2 (ERBB2) Immunohistochemistry in Non-Small Cell Lung Cancer: Does Expression Correlate with ERBB2 Mutational Status?
    Cardillo, Anthony
    Kovar, Sierra
    Hicks, David
    Velez, Moises
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 1094 - 1095
  • [28] HER2 (ERBB2) Immunohistochemistry in Non-Small Cell Lung Cancer: Does Expression Correlate with ERBB2 Mutational Status?
    Cardillo, Anthony
    Kovar, Sierra
    Hicks, David
    Velez, Moises
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1094 - 1095
  • [29] ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
    Joshi, Sunil K.
    Keck, Jamie M.
    Eide, Christopher A.
    Bottomly, Daniel
    Traer, Elie
    Tyner, Jeffrey W.
    McWeeney, Shannon K.
    Tognon, Cristina E.
    Druker, Brian J.
    LEUKEMIA, 2020, 34 (10) : 2798 - 2804
  • [30] Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer
    Kloth, Michael
    Ruesseler, Vanessa
    Engel, Christoph
    Koenig, Katharina
    Peifer, Martin
    Mariotti, Erika
    Kuenstlinger, Helen
    Florin, Alexandra
    Rommerscheidt-Fuss, Ursula
    Koitzsch, Ulrike
    Wodtke, Claudia
    Ueckeroth, Frank
    Holzapfel, Stefanie
    Aretz, Stefan
    Propping, Peter
    Loeffler, Markus
    Merkelbach-Bruse, Sabine
    Odenthal, Margarete
    Friedrichs, Nicolaus
    Heukamp, Lukas Carl
    Zander, Thomas
    Buettner, Reinhard
    GUT, 2016, 65 (08) : 1296 - 1305
12345